Evidence map›Paper›PMID 41180991›Full record

ArticleWorld journal of gastroenterology2025

Breaking barriers in the first-line

Vasily Isakov, Alexei Goncharov

Abstract readEditorial
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vasily IsakovDepartment of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia. vasily.isakov@gmail.com.
Alexei GoncharovDepartment of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global burden of

Indexed as

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriProton Pump InhibitorsPyrrolesSulfonamidesAmoxicillinChinaClarithromycinCytochrome P-450 CYP2C19Drug Resistance, BacterialDrug Therapy, CombinationEast Asian PeopleHumansMulticenter Studies as TopicRandomized Controlled Trials as Topic1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAmoxicillinAnti-Bacterial AgentsClarithromycinCYP2C19 protein, humanCytochrome P-450 CYP2C19Proton Pump InhibitorsPyrrolesSulfonamidesFirst-line treatmentHelicobacter pyloriProton pump inhibitorsTriple therapyVonoprazan

Identifiers

PMID41180991
PMCPMC12576554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.